Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

Summary

The purpose of this research study is to test the safety and efficacy (how well it works) of exenatide as a treatment for weight gain associated with olanzapine in obese adults with Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder Exenatide has been approved by the FDA for the treatment of Type 2 diabetes. It has not been approved for the treatment of weight gain associated with olanzapine in obese adults with bipolar disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder

Timeline

Start

2008-12

Primary completion

2015-07

Completion

2015-07

Publications

• Patino LR, Strawn JR, Adler CM, Blom TJ, Welge JA, DelBello MP. A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults. J Affect Disord. 2025 Aug 1;382:116-122. doi: 10.1016/j.jad.2025.04.046. Epub 2025 Apr 7.

Drugs

Indications

No indication recorded.